Skip to main content

Articles

Page 27 of 38

  1. With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2...

    Authors: Shundong Cang, Chaitanya Iragavarapu, John Savooji, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2015 8:129
  2. EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). Howeve...

    Authors: Shuhang Wang, Xiaomei Su, Hua Bai, Jun Zhao, Jianchun Duan, Tongtong An, Minglei Zhuo, Zhijie Wang, Meina Wu, Zhenxiang Li, Jian Zhu and Jie Wang
    Citation: Journal of Hematology & Oncology 2015 8:127
  3. Acute promyelocytic leukemia (APL) is associated with chromosomal translocation t(15;17), which results in the proliferation of morphologically abnormal promyelocytes. Gain of supernumerary copies of the 8q24 ...

    Authors: Chengwu Zeng, Xibao Yu, Jing Lai, Lijiang Yang, Shaohua Chen and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2015 8:126
  4. Although progress in children, in adults, ALL still carries a dismal outcome. Here, we explored the in vitro and in vivo activity of PF-00477736 (Pfizer), a potent, selective ATP-competitive small-molecule inh...

    Authors: Ilaria Iacobucci, Andrea Ghelli Luserna Di Rorà, Maria Vittoria Verga Falzacappa, Claudio Agostinelli, Enrico Derenzini, Anna Ferrari, Cristina Papayannidis, Annalisa Lonetti, Simona Righi, Enrica Imbrogno, Silvia Pomella, Claudia Venturi, Viviana Guadagnuolo, Federica Cattina, Emanuela Ottaviani, Maria Chiara Abbenante…
    Citation: Journal of Hematology & Oncology 2015 8:125
  5. Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition h...

    Authors: Katy K. Tsai and Adil I. Daud
    Citation: Journal of Hematology & Oncology 2015 8:123
  6. Hepatocellular carcinoma (HCC) displays high resistance to conventional chemotherapy. Considering that microRNA-122 (miR-122) performs an essential function to promote chemosensitivity of HCC cells, an effecti...

    Authors: Guohua Lou, Xiuli Song, Fan Yang, Shanshan Wu, Jing Wang, Zhi Chen and Yanning Liu
    Citation: Journal of Hematology & Oncology 2015 8:122
  7. Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoid malignancy worldwide. Approximately 5 % of cases of DLBCL are so-called double-hit lymphomas (DHL), defined by a chromosomal translocat...

    Authors: Lan V. Pham, Gary Lu, Archito T. Tamayo, Juan Chen, Pramoda Challagundla, Jeffrey L. Jorgensen, L. Jeffrey Medeiros and Richard J. Ford
    Citation: Journal of Hematology & Oncology 2015 8:121
  8. Nemo-like kinase (NLK) is an evolutionarily conserved serine/threonine kinase that regulates the activity of a wide range of signal transduction pathways. Metformin, an oral antidiabetic drug, is used for canc...

    Authors: Dong Suwei, Zeng Liang, Liu Zhimin, Li Ruilei, Zou Yingying, Li Zhen, Ge Chunlei, Lai Zhangchao, Xue Yuanbo, Yang Jinyan, Li Gaofeng and Song Xin
    Citation: Journal of Hematology & Oncology 2015 8:120

    The Erratum to this article has been published in Journal of Hematology & Oncology 2016 9:11

  9. Urothelial cancers (UC) are the fourth most common tumours worldwide after prostate (or breast), lung and colorectal cancer. Despite recent improvements in their management, UC remain an aggressive disease ass...

    Authors: Alejo Rodriguez-Vida, Matilde Saggese, Simon Hughes, Sarah Rudman, Simon Chowdhury, Neil R. Smith, Peter Lawrence, Claire Rooney, Brian Dougherty, Donal Landers, Elaine Kilgour and Hendrik-Tobias Arkenau
    Citation: Journal of Hematology & Oncology 2015 8:119
  10. This report focuses on the adaptive phase I trial design aimed to find the clinically applicable dose for decitabine maintenance treatment after allogeneic hematopoietic stem cell transplantation in patients w...

    Authors: Seunghoon Han, Yoo-Jin Kim, Jongtae Lee, Sangil Jeon, Taegon Hong, Gab-jin Park, Jae-Ho Yoon, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Ki-Seong Eom, Hee-Je Kim, Chang-Ki Min, Seok Lee and Dong-Seok Yim
    Citation: Journal of Hematology & Oncology 2015 8:118
  11. HTLV-I is associated with the development of an aggressive form of lymphocytic leukemia known as adult T-cell leukemia/lymphoma (ATLL). A major obstacle for effective treatment of ATLL resides in the genetic d...

    Authors: Xue Tao Bai, Ramona Moles, Hassiba Chaib-Mezrag and Christophe Nicot
    Citation: Journal of Hematology & Oncology 2015 8:117
  12. Prolonged isolated thrombocytopenia (PT) is a frequent complication in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is associated with an adverse prognosis. In th...

    Authors: Xiao-Hui Zhang, Qian-Ming Wang, Jia-Min Zhang, Fei-Er Feng, Feng-Rong Wang, Huan Chen, Yuan-Yuan Zhang, Yu-Hong Chen, Wei Han, Lan-Ping Xu, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2015 8:116
  13. Recent studies have identified myocyte enhancer factor 2C (MEF2C) as cooperating oncogene in acute myeloid leukemia (AML) and suggested a contribution to the aggressive nature of at least some subtypes of AML, ra...

    Authors: George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Alex Kentsis, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi and Roland B. Walter
    Citation: Journal of Hematology & Oncology 2015 8:115

    The Erratum to this article has been published in Journal of Hematology & Oncology 2016 9:133

  14. Therapy and outcome for elderly acute myeloid leukemia (AML) patients has not improved for many years. Similarly, there remains a clinical need to improve response rates in advanced myelodysplastic syndrome (M...

    Authors: Raoul Tibes, Aref Al-Kali, Gavin R Oliver, Devora H Delman, Nanna Hansen, Keerthi Bhagavatula, Jayaram Mohan, Fariborz Rakhshan, Thomas Wood, James M. Foran, Ruben A. Mesa and James M. Bogenberger
    Citation: Journal of Hematology & Oncology 2015 8:114
  15. Adoptive cell therapy (ACT) is rapidly migrating from bench to clinical therapy for hematological malignancies. Recently, a new subtype of memory T cells, stem cell memory T (TSCM) cells, was shown to be one of t...

    Authors: Ling Xu, Yikai Zhang, Gengxin Luo and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2015 8:113
  16. The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to thera...

    Authors: Thomas Köhnke, Christina Krupka, Johanna Tischer, Thomas Knösel and Marion Subklewe
    Citation: Journal of Hematology & Oncology 2015 8:111
  17. Gap junctional intercellular communication (GJIC) is typically decreased in malignant tumors. Gap junction is not presented between hematopoietic cells but occurred in bone marrow stromal cells (BMSCs). Connex...

    Authors: Yao Liu, Qin Wen, Xue-lian Chen, Shi-jie Yang, Lei Gao, Li Gao, Cheng Zhang, Jia-li Li, Xi-xi Xiang, Kai Wan, Xing-hua Chen, Xi Zhang and Jiang-fan Zhong
    Citation: Journal of Hematology & Oncology 2015 8:110
  18. Small cell carcinoma/neuroendocrine prostate cancer (NePC) is a lethal, poorly understood prostate cancer (PCa) subtype. Controversy exists about the origin of NePC in this setting.

    Authors: Kunal C. Kadakia, Scott A. Tomlins, Saagar K. Sanghvi, Andi K. Cani, Kei Omata, Daniel H. Hovelson, Chia-Jen Liu and Kathleen A. Cooney
    Citation: Journal of Hematology & Oncology 2015 8:109
  19. B-acute lymphoblastic leukemia (B-ALL) is derived from B cell progenitors. Recently, the development of appropriate combinations of chemotherapy and immunotherapy represents a promising approach for eliminatin...

    Authors: Dongmei Fan, Wei Li, Yuqi Yang, Xiaolong Zhang, Qing Zhang, Yan Yan, Ming Yang, Jianxiang Wang and Dongsheng Xiong
    Citation: Journal of Hematology & Oncology 2015 8:108
  20. In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-v...

    Authors: Frédéric Baron, Myriam Labopin, Annalisa Ruggeri, Mohamad Mohty, Guillermo Sanz, Noel Milpied, Andrea Bacigalupo, Alessandro Rambaldi, Francesca Bonifazi, Alberto Bosi, Jorge Sierra, Ibrahim Yakoub-Agha, Josep Maria Ribera Santasusana, Eliane Gluckman and Arnon Nagler
    Citation: Journal of Hematology & Oncology 2015 8:107
  21. Multiple myeloma (MM) is an incurable haematological malignancy characterised by the clonal proliferation of malignant plasma cells within the bone marrow. We have previously identified pituitary tumour transf...

    Authors: Jacqueline E. Noll, Kate Vandyke, Duncan R. Hewett, Krzysztof M. Mrozik, Rachel J. Bala, Sharon A. Williams, Chung H. Kok and Andrew CW Zannettino
    Citation: Journal of Hematology & Oncology 2015 8:106
  22. Members of the Eph/ephrin gene families act as key regulators of cerebellar development during embryogenesis. Aberrant signaling of Eph family of receptor tyrosine kinases and their ephrin ligands has also bee...

    Authors: Shilpa Bhatia, Kellen Hirsch, Nimrah A. Baig, Olga Rodriguez, Olga Timofeeva, Kevin Kavanagh, Yi Chien Lee, Xiao-Jing Wang, Christopher Albanese and Sana D. Karam
    Citation: Journal of Hematology & Oncology 2015 8:105
  23. Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell r...

    Authors: Jingjing Wu, Jiaping Fu, Mingzhi Zhang and Delong Liu
    Citation: Journal of Hematology & Oncology 2015 8:104
  24. The oral proteasome inhibitor ixazomib is under phase 3 clinical investigation in multiple myeloma (MM) in combination with lenalidomide–dexamethasone. This study was conducted to investigate the pharmacokinet...

    Authors: Neeraj Gupta, Yeow Tee Goh, Chang-Ki Min, Jae Hoon Lee, Kihyun Kim, Raymond S. M. Wong, Chor Sang Chim, Michael J. Hanley, Huyuan Yang, Karthik Venkatakrishnan, Ai-Min Hui, Dixie-Lee Esseltine and Wee Joo Chng
    Citation: Journal of Hematology & Oncology 2015 8:103
  25. Addition of high-dose cytarabine (HDCA) to the conventional cyclophosphamide/total-body irradiation (CY/TBI) regimen significantly improved prognosis after cord blood transplantation (CBT) for adult acute myel...

    Authors: Yasuyuki Arai, Kazunari Aoki, June Takeda, Tadakazu Kondo, Tetsuya Eto, Shuichi Ota, Hisako Hashimoto, Takahiro Fukuda, Yukiyasu Ozawa, Yoshinobu Kanda, Chiaki Kato, Mineo Kurokawa, Koji Iwato, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta…
    Citation: Journal of Hematology & Oncology 2015 8:102
  26. Herein, we describe the establishment and characterization of the first mixed-phenotype acute leukemia cell line (JIH-5). The JIH-5 cell line was established from leukemia cells with B lymphoid/myeloid phenoty...

    Authors: Nana Ping, Huiying Qiu, Qian Wang, Haiping Dai, Changgeng Ruan, Stefan Ehrentraut, Hans G. Drexler, Roderick A. F. MacLeod and Suning Chen
    Citation: Journal of Hematology & Oncology 2015 8:100
  27. Neuroblastoma currently has poor prognosis, therefore we proposed a new strategy by targeting neuroblastoma with genetically engineered anaerobic Salmonella (Sal-YB1).

    Authors: Zhu-Ling Guo, Bin Yu, Bo-Tao Ning, Shing Chan, Qiu-Bin Lin, James Chun-Bong Li, Jian-Dong Huang and Godfrey Chi-Fung Chan
    Citation: Journal of Hematology & Oncology 2015 8:99
  28. The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective agai...

    Authors: Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Juri Sakuta and Kazuma Ohyashiki
    Citation: Journal of Hematology & Oncology 2015 8:97
  29. Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical de...

    Authors: Jingjing Wu, Jiaping Fu, Mingzhi Zhang and Delong Liu
    Citation: Journal of Hematology & Oncology 2015 8:96
  30. Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor...

    Authors: Wei Sun, Xun Yuan, Yijun Tian, Hua Wu, Hanxiao Xu, Guoqing Hu and Kongming Wu
    Citation: Journal of Hematology & Oncology 2015 8:95
  31. Bcl11b is a transcription factor important for T cell development and also a tumor-suppressor gene that is hemizygously inactivated in ~10 % human T cell acute lymphoblastic leukemia (T-ALL) and several murine...

    Authors: Kerice A. Pinkney, Wenxia Jiang, Brian J. Lee, Denis G. Loredan, Chen Li, Govind Bhagat and Shan Zha
    Citation: Journal of Hematology & Oncology 2015 8:94
  32. T cell function is crucial for the success of several novel immunotherapeutic strategies for the treatment of acute myeloid leukemia (AML). However, changes in phenotype and function of T cells have been descr...

    Authors: Frauke M. Schnorfeil, Felix S. Lichtenegger, Katharina Emmerig, Miriam Schlueter, Julia S. Neitz, Rika Draenert, Wolfgang Hiddemann and Marion Subklewe
    Citation: Journal of Hematology & Oncology 2015 8:93
  33. The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastat...

    Authors: Gaurav Goel and Weijing Sun
    Citation: Journal of Hematology & Oncology 2015 8:92
  34. Since the introduction of tyrosine kinase inhibitors (TKIs) into combination chemotherapy regimens, the majority of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patie...

    Authors: Li Gao, Cheng Zhang, Lei Gao, Yao Liu, Yi Su, Sanbin Wang, Bin Li, Tonghua Yang, Zhong Yuan and Xi Zhang
    Citation: Journal of Hematology & Oncology 2015 8:90
  35. Gliomas are the most common types of primary brain tumors in the adult central nervous system. TMEM140 is identified as an amplified gene in the human gastric cancer genome. However, the function of TMEM140 in...

    Authors: Bin Li, Ming-Zhu Huang, Xiao-Qiang Wang, Bang-Bao Tao, Jun Zhong, Xu-Hui Wang, Wen-Chuan Zhang and Shi-Ting Li
    Citation: Journal of Hematology & Oncology 2015 8:89

    The Erratum to this article has been published in Journal of Hematology & Oncology 2015 8:101

  36. Alterations in DNA methylation are seen in cancers and have also been examined in clear cell renal cell carcinoma (ccRCC). Numerous tumor suppressor genes have been reported to be partially or completely silen...

    Authors: Niraj Shenoy, Nishanth Vallumsetla, Yiyu Zou, Jose Nahun Galeas, Makardhwaj Shrivastava, Caroline Hu, Katalin Susztak and Amit Verma
    Citation: Journal of Hematology & Oncology 2015 8:88
  37. The unfolded protein response (UPR), an endoplasmic reticulum (ER) stress-induced signaling cascade, is mediated by three major stress sensors IRE-1α, PERK, and ATF6α. Studies described the UPR as a critical n...

    Authors: Behzad Kharabi Masouleh, Eric Chevet, Jens Panse, Edgar Jost, Michael O’Dwyer, Tim H. Bruemmendorf and Afshin Samali
    Citation: Journal of Hematology & Oncology 2015 8:87
  38. Small studies suggest an association of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) with primary graft failure (GF) following haploidentical stem cell transplantation, but primary graft...

    Authors: Ying-Jun Chang, Xiang-Yu Zhao, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Wei Han, Huan Chen, Feng-Rong Wang, Xiao-Dong Mo, Yuan-Yuan Zhang, Ming-Rui Huo, Xiao-Su Zhao, Kong Y, Kai-Yan Liu and Xiao-Jun Huang
    Citation: Journal of Hematology & Oncology 2015 8:84
  39. Exosomes have emerged as a novel mode of intercellular communication. Exosomes can shuttle bioactive molecules including proteins, DNA, mRNA, as well as non-coding RNAs from one cell to another, leading to the...

    Authors: Xu Zhang, Xiao Yuan, Hui Shi, Lijun Wu, Hui Qian and Wenrong Xu
    Citation: Journal of Hematology & Oncology 2015 8:83
  40. Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy. The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia. In ...

    Authors: Min-Wu Chao, Mei-Jung Lai, Jing-Ping Liou, Ya-Ling Chang, Jing-Chi Wang, Shiow-Lin Pan and Che-Ming Teng
    Citation: Journal of Hematology & Oncology 2015 8:82
  41. Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented effectiveness of BCR-ABL inhibitors in treating chronic myeloid leukemia, development of resistance is a continuous clinical chal...

    Authors: Sara Redaelli, Pietro Perini, Monica Ceccon, Rocco Piazza, Roberta Rigolio, Mario Mauri, Frank Boschelli, Athina Giannoudis and Carlo Gambacorti-Passerini
    Citation: Journal of Hematology & Oncology 2015 8:81
  42. The infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out ...

    Authors: Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, William J. Hogan and Svetomir N. Markovic
    Citation: Journal of Hematology & Oncology 2015 8:80

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here